Home/Filings/4/0001209191-17-015978
4//SEC Filing

ARCA biopharma, Inc. 4

Accession 0001209191-17-015978

$ORKACIK 0000907654operating

Filed

Feb 28, 7:00 PM ET

Accepted

Mar 1, 5:10 PM ET

Size

10.1 KB

Accession

0001209191-17-015978

Insider Transaction Report

Form 4
Period: 2017-02-27
BRISTOW MICHAEL R
DirectorChief Science and Med. Officer
Transactions
  • Sale

    Common Stock

    2017-02-28$2.61/sh763$1,99141,875 total
  • Award

    Stock Option (right to buy)

    2017-02-27+41,60041,600 total
    Exercise: $2.60Exp: 2027-02-26Common Stock (41,600 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    19,986
  • Common Stock

    (indirect: By IRA)
    25,459
Footnotes (3)
  • [F1]Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan")
  • [F2]Includes (i) remaining 2,025 previously reported shares issued as RSUs under the Plan that vest on 2/27/18, and (ii) 4,581 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 35,269 previously reported shares of common stock held directly.
  • [F3]Grant to the Reporting Person of a stock option under the Plan, 50% vesting upon achievement of certain pre-specified corporate milestone related to the outcome of the interim data analysis by that trial's Data and Safety Monitoring Board, and if the milestone is achieved, the remainder of the grant will vest on March 31, 2018, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. If the corporate milestone is not achieved, the Option will be cancelled. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.

Issuer

ARCA biopharma, Inc.

CIK 0000907654

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000907654

Filing Metadata

Form type
4
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 5:10 PM ET
Size
10.1 KB